Monthly Prescribing Reference7h
FDA Approves Vimkunya to Protect Against Chikungunya Virus
Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.
FiercePharma7h
Bavarian Nordic catches up to rival Valneva with broad chikungunya vaccine approval from FDA
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
JD Supra9h
UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine
Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
GlobalData on MSN1d
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...
Bavarian Nordic gets FDA approval for chikungunya vaccine
Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.